AIM ImmunoTech Inc. announced today that the Japan Patent Office has issued a patent covering the company’s proprietary use of Ampligen® (Rintatolimod) in combination with checkpoint inhibitors for the treatment of cancer. This patent, which does not expire until December 20, 2039, significantly strengthens AIM's intellectual property portfolio in Japan, the third-largest pharmaceutical market globally.
The allowed claims in Japan are broad, encompassing multiple cancer types including pancreatic, skin, colorectal, ovarian, melanoma, breast/triple-negative breast, head and neck, bladder, renal cell carcinoma, and lung cancer. The patent also captures specific dosing regimens, administration routes, and synergistic therapeutic effects observed when Ampligen is combined with checkpoint inhibitors.
This patent reinforces AIM's ability to advance its clinical pipeline, secure strategic collaborations, and capture value in the growing global immuno-oncology sector. AIM also holds similar patents in the U.S. (expires August 9, 2039) and the Netherlands (expires December 19, 2039), further solidifying its competitive position for Ampligen combination therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.